Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 14,924 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Disorders Clear all
Completed Phase 2 Interventional Results available

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

NCT03697564
View directory record Official record
Conditions
Pancreatic Cancer Stage IV
Interventions
Gemcitabine, Nivolumab 10 MG/ML Intravenous Solution [OPDIVO], Cabiralizumab
Drug
Lead sponsor
Hitendra Patel
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

NCT00538434
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Reslizumab, Saline
Biological · Other
Lead sponsor
Ception Therapeutics
Industry
Eligibility
5 Years to 18 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 22, 2026, 4:01 AM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision

NCT01188109
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreatic Cancer
Interventions
Gemcitabine, Cisplatin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers

NCT02642809
View directory record Official record
Conditions
Esophageal Cancer, Cancer of the Esophagus
Interventions
Pembrolizumab, Brachytherapy
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 22, 2026, 4:01 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Benralizumab in Patients With Eosinophilic Esophagitis

NCT04543409
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Benralizumab, Matching placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 65 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
22
States / cities
Little Rock, Arkansas • St. Petersburg, Florida • Atlanta, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 22, 2026, 4:01 AM EDT
Active, not recruiting Phase 4 Interventional

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

NCT06101095
View directory record Official record
Conditions
Eosinophilic Oesophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Murrieta, California • San Francisco, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 4:01 AM EDT
Recruiting Phase 2 Interventional

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075
View directory record Official record
Conditions
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers
Interventions
Belzutifan
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
12 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
14
States / cities
Los Angeles, California • Chicago, Illinois • Warrenville, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 4:01 AM EDT
Completed No phase listed Observational

Study of Ultrasound of the Eye for Children With Suspected Shunt Failure

NCT00743457
View directory record Official record
Conditions
Hydrocephalus
Interventions
Ocular Ultrasound
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
6 Months to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 22, 2026, 4:01 AM EDT
Completed No phase listed Observational

Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin

NCT00831571
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Small Bowel Cancer, Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma

NCT01757171
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma, Distal Esophageal Adenocarcinoma
Interventions
Cabazitaxel
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
5
States / cities
San Francisco, California • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of Experience on Results With the Third Eye Retroscope

NCT00969124
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Third Eye Retroscope
Device
Lead sponsor
Avantis Medical Systems
Industry
Eligibility
Not listed
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
9
States / cities
Celebration, Florida • Chicago, Illinois • Evanston, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Phase 2 Interventional

Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene

NCT00303927
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
capecitabine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2010 · Synced Oct 22, 2026, 4:01 AM EDT
Completed No phase listed Observational

Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration

NCT02226666
View directory record Official record
Conditions
Liver Tumor
Interventions
MRI with Multihance, MRI with Eovist
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient-Centered Care and Asian Americans

NCT02139722
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, Liver Disease
Interventions
Video Doctor, PA + PPN
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 22, 2026, 4:01 AM EDT
Withdrawn Phase 4 Interventional

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

NCT04614142
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Hepatitis c
Interventions
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
34 Years to 44 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 22, 2026, 4:01 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Preventing Early-Onset Colorectal Cancer in the VA

NCT07071454
View directory record Official record
Conditions
Colorectal Neoplasms, Mass Screening
Interventions
Patient intervention, PCP intervention
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years to 49 Years
Enrollment
536 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Phase 1 Interventional

BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies

NCT00207051
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Brivanib + Cetuximab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Physical Activity in Overweight Girls: Implications for Reversing Risk Factors for Type 2 Diabetes

NCT01323088
View directory record Official record
Conditions
Abdominal Obesity, Physical Activity
Interventions
Control, Resistance Exercise, Aerobic exercise
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Oct 22, 2026, 4:01 AM EDT
Completed No phase listed Observational Results available

Alpha-1 Carrier Genomics Study

NCT02810327
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency, Emphysema, COPD, Smoking
Interventions
Genetic Sequencing
Genetic
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Phase 2 Interventional Results available

A Study of IDN-6556 in Subjects With Liver Cirrhosis

NCT02230670
View directory record Official record
Conditions
Liver Cirrhosis, Hepatic Cirrhosis
Interventions
IDN-6556, Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Colonoscopy Screening: Setting Epic Follow-up Times

NCT05631873
View directory record Official record
Conditions
Concordance Between Colonoscopy Follow up Interval Noted in Patient Letters vs. Electronic Health Record Chart, Colorectal Cancer
Interventions
Assistance with implementing Epic Smartlist
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 22, 2026, 4:01 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease

NCT04173273
View directory record Official record
Conditions
Crohn's Disease
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
192
States / cities
Dothan, Alabama • Mobile, Alabama • Peoria, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 22, 2026, 4:01 AM EDT
Active, not recruiting Not applicable Interventional

Electronic Neurocognitive Tools in Screening for Mental Capability in Patients Undergoing Liver Surgery

NCT03678441
View directory record Official record
Conditions
Liver and Intrahepatic Bile Duct Disorder
Interventions
BrainCheck Cognitive Assessment, Cognitive Assessment
Behavioral · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 22, 2026, 4:01 AM EDT
Completed No phase listed Observational

Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract

NCT01770405
View directory record Official record
Conditions
Pancreatic Cyst, Pancreatic Neoplasms, Pancreatic Adenoma, Pancreatic Cancer, Pancreatic Islet Cell Tumors, Lymph Node Mass, Lymphadenopathy, GIST
Interventions
Endoscopic ultrasound fine needle aspiration
Device
Lead sponsor
Mauna Kea Technologies
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Atlanta, Georgia • Manhasset, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 22, 2026, 4:01 AM EDT